ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2014
GOLPH3 high expression predicts poor prognosis in patients with resected non-small cell lung cancer: an immunohistochemical analysis.
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Golgi phosphoprotein3 overexpression is associated with poor survival in patients with solid tumors: a meta-analysis.International journal of clinical and experimental pathology · 2015Pooled it
- Oncogenic receptor tyrosine kinase signaling is driven by the Golgi protein GOLPH3 and its interaction with MYO18A.Science signaling · 2026Article
- Golgi Drivers of Cancer.Sub-cellular biochemistry · 2026Review
- Review
- Golgi Phosphoprotein 3 Promotes Colon Cancer Cell Metastasis Through STAT3 and Integrin α3 Pathways.Frontiers in molecular biosciences · 2022Article
- Oncogenic Roles of GOLPH3 in the Physiopathology of Cancer.International journal of molecular sciences · 2020Review
- Diagnostic Utility of Serum Golgi Phosphoprotein 3 in Bladder Cancer Patients.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- GOLPH3: a Golgi phosphatidylinositol(4)phosphate effector that directs vesicle trafficking and drives cancer.Journal of lipid research · 2019Review
- Clinicopathologic Features and Prognostic Implications of Golgi Phosphoprotein 3 in Non-small Cell Lung Cancer: A Meta-analysis.Journal of Cancer · 2019Article
- Article
- GOLPH3 overexpression correlates with poor response to neoadjuvant therapy and prognosis in locally advanced rectal cancer.Oncotarget · 2016Article
- [Effect of phosphoinositide 4-phosphate on invasion and migration of human glioma U87 cells].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2016Article
- Copy number analysis of whole-genome data using BIC-seq2 and its application to detection of cancer susceptibility variants.Nucleic acids research · 2016Article
- Downregulation of HIF-1α inhibits the proliferation and invasion of non-small cell lung cancer NCI-H157 cells.Oncology letters · 2016Article
- miR-186 inhibits cell proliferation of prostate cancer by targeting GOLPH3.American journal of cancer research · 2016Article
- Article
- Distinct Biochemical Pools of Golgi Phosphoprotein 3 in the Human Breast Cancer Cell Lines MCF7 and MDA-MB-231.PloS one · 2016Article
- Review
- GOLPH3 links the Golgi, DNA damage, and cancer.Cancer research · 2015Review
- Golgi phosphoprotein 3 regulates metastasis of prostate cancer via matrix metalloproteinase 9.International journal of clinical and experimental pathology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Golgi phosphoprotein 3 (GOLPH3) has been reported to be involved in the development of several human tumours. However, little is known about GOLPH3 expression and its clinical significance in non-small cell lung cancer (NSCLC). The present study was conducted to investigate the expression of GOLPH3 and its prognostic significance in NSCLC. Immunohistochemical analysis was used to determine the expression of GOLPH3 in 145 cases NSCLC tissue and their corresponding adjacent normal tissues. The results are the following: (1) The GOLPH3 protein was mainly located in the cytoplasm of NSCLC tissue; (2) GOLPH3 was highly expressed in 71.7% of NSCLC tissues versus 22.8% of adjacent tissues (P < 0.01); (3) GOLPH3 expression was significantly associated with tumour-node-metastasis (TNM) stage (P = 0.001), lymph node status (P = 0.014), and degree of differentiation (P = 0.018); (4) The Kaplan-Meier curve indicated that the patients with high GOLPH3 expression had significantly shorter survival than those with low GOLPH3 expression; and (5) Cox regression analysis demonstrated that the expression of GOLPH3, lymph node status, and TNM stage were independent prognostic predictors for NSCLC patients. High GOLPH3 expression is predictive of poor prognosis of NSCLC, implying that GOLPH3 may be a promising new target for targeted therapies for NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.